Suzanne Lind, MD
Child & Adolescent Psychiatry · New Brunswick, NJNPI 1437250644
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Teva Pharmaceuticals USA, Inc. accounts for 62.2% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $12,165, more than ten times the $568 reported in 2019. Among child & adolescent psychiatry clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 554 payments — averaging $33.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$11K
- Alkermes, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$1K
- Neurocrine Biosciences, Inc.$956
- Otsuka America Pharmaceutical, Inc.$439
- plus $1K from 12 others
What the payments were for
- Speaking & faculty fees$9,03049%
- Food & beverage$8,82048%
- Education$5483%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 163 | $11,449 |
| Alkermes, Inc. | 84 | $1,818 |
| AbbVie | 75 | $1,211 |
| Johnson & Johnson | 74 | $1,109 |
| Neurocrine Biosciences, Inc. | 50 | $956 |
| Otsuka America Pharmaceutical, Inc. | 27 | $439 |
| E.r. Squibb & Sons, L.L.C. | 24 | $380 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 11 | $314 |
| Lundbeck LLC | 13 | $205 |
| Luye Pharma (USA) Ltd. | 8 | $136 |
| Vanda Pharmaceuticals Inc. | 8 | $105 |
| Almatica Pharma LLC | 6 | $101 |
| Indivior Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $48 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Bioxcel Therapeutics, Inc. | 1 | $17 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $14 |
| Avanir Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$9,232
- LYBALVI$968
- ARISTADA$959
- INGREZZA$258
- ARISTADA INITIO$240
- COBENFY$125
- CAPLYTA$124
- Austedo XR$120
- SPRAVATO$106
How this compares
$18,398 in reported general payments places this provider in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
See all child & adolescent psychiatry providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 58 | $175,575 |
| Austedo XrDeutetrabenazine | 17 | $127,045 |
| AustedoDeutetrabenazine | 12 | $100,577 |
| IngrezzaValbenazine Tosylate | 12 | $90,628 |
| AristadaAripiprazole Lauroxil | 24 | $85,005 |
| Abilify MaintenaAripiprazole | 13 | $36,070 |
| LybalviOlanzapine/Samidorphan Malate | 16 | $25,186 |
| Paliperidone ErPaliperidone | 50 | $6,271 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 39 | $4,275 |
| Divalproex Sodium ErDivalproex Sodium | 111 | $3,974 |
| Ziprasidone Hcl | 66 | $3,515 |
| Bupropion XlBupropion Hcl | 94 | $3,355 |
| Clonazepam | 152 | $2,470 |
| Haloperidol Lactate | 16 | $2,431 |
| Aripiprazole | 84 | $2,278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr, Austedo | $11,449 | $227,62229 claims |
| Johnson & JohnsonInvega Sustenna | $1,109 | $175,57558 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,818 | $110,19140 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $956 | $90,62812 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $439 | $36,07013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 137 child & adolescent psychiatry providers in New Jersey.
Other child & adolescent psychiatry in New Brunswick
- Ravinder BhallaRidgewood$125K
- Steven DyckmanEast Brunswick$53K
- Eric BartkyLivingston$51K
- Bohdan CzartoryskyParsippany$21K
- Akhtar HossainSomerville$19K
- Aykut OzdenEdgewater$17K
- Valeria KorshunovaHackensack$12K
- Carol DobrzynskiBrick$10K
- Saranga BhallaPrinceton$5K
- Tahir KhwajaNorth Brunswick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.